Kornimate/medical-research-clean huggingface dataset:
patient-initiated and controlled oral refeeding (pictor)

Conditions: Acute Pancreatitis

Summary: the first step in treating patients with acute pancreatitis is to provide pain relief and intravenous fluids to keep them comfortable. as the pain subsides and patient starts to feel better food and fluids by mouth are restarted. this is done to rest the pancreas which is the organ that has been inflamed. in some patients when food by mouth restarts they have pain and as a consequence they have a longer stay in hospital. it is thought that patients who have little pain and are within 24 hours of admission to hospital do well if they control their own food intake. this is in contrast to the usual treatment where the treating team advise when eating should restart.


Eligibility criteria:
inclusion criteria: * diagnosis of acute pancreatitis * age \> 18 years * written informed consent exclusion criteria: * ongoing need for opiates * \>96 hours after onset of symptoms * chronic pancreatitis * post-ercp pancreatitis * intraoperative diagnosis * pregnancy * malignancy * received nutrition before randomisation

Keywords: acute pancreatitis, nutrition
safety and tolerability of spd503 and psychostimulants in children and adolescents aged 6-17 with attention-deficit/hyperactivity disorder (adhd)

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: the purpose of this study is to assess the safety and tolerability of administering spd503 (guanfacine hydrochloride) with psychostimulants (amphetamine or methylphenidate) for treatment of adhd in children and adolescents aged 6-17


Eligibility criteria:
inclusion criteria: * subjects with a primary diagnosis of adhd * subject on a stable dose of a psychostimulant approved for the treatment of adhd for at least 1 month, with sub-optimal control in the investigator's opinion * male or non-pregnant female subject who agrees to comply with any applicable contraceptive requirements exclusion criteria: * subject has current uncontrolled comorbid psychiatric diagnosis (except odd and mild anxiety) with significant symptoms * history of seizure during the last 2 years * subject has any specific cardiac condition or family history of significant cardiac condition * subject is pregnant or lactating
european drug utilization study

Conditions: Major Depressive Disorder (MDD)

Summary: the purpose of this retrospective observational study is to evaluate the characteristics of patients receiving seroquel xr as treatment for their major depressive disorder. the study will also investigate how the medication is used for these patients and if there are any differences in drug utilisation between the included countries. the study is observing patients initiating seroquel xr during a 9 month period corresponding to 3 to 12 months following the launch of the product in each country for the mdd indication. a drug utilisation questionnaire will be used to collect study data from patients' medical records.

a multinational, multicenter, retrospective, observational drug utilisation study of seroquel extended release (xr) prescribed by psychiatrists as treatment for major depressive disorder (mdd) in selected countries in the european union (eu)

Eligibility criteria:
inclusion criteria: * provision of informed consent before initiation of any collection of questionnaire data. * documented clinical diagnosis of major depressive disorder, single episode, or recurrent. * initiation of seroquel xr for treatment of mdd during the period defining the inception cohort, i.e. from 3 months after launch until the index date (12 months after launch). exclusion criteria: * if participating in any clinical trial during the time from 3 months after launch until the index date, the patient cannot take part in this study.

Keywords: seroquel xr quetiapine xr drug utilization major depressive disorder (mdd)
exercise as a preventive agent to combat immobility in patients with ovarian or endometrial cancers receiving chemotherapy

Conditions: Ovarian Cancer; Ovarian Carcinoma; Ovarian Cancer Stage IV; Ovarian Cancer Stage III; Ovarian Cancer Stage 3; Endometrial Cancer; Endometrial Cancer Stage

Summary: the purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (cipn; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).

this research study is a randomized controlled trial that will compare an exercise group to a control group on lower extremity function, cipn, and inflammatory markers in ovarian or endometrial cancer patients undergoing first-line chemotherapy after surgery. the names of the study interventions involved in this study are/is: * aerobic and resistance exercise; virtually supervised 16-week aerobic and resistance exercise performed at home via zoom * attention control for 16 weeks, home-based stretching the research study procedures include: screening for eligibility and study interventions including evaluations and follow up visits. it is expected that about 30 people will take part in this research study.

Eligibility criteria:
inclusion criteria: * newly diagnosed patients with stages iii-iv ovarian or endometrial cancer * receiving first-line carboplatin and paclitaxel chemotherapy after surgery * ≥18 years, children under the age of 18 will be excluded due to rarity of disease * physician's clearance to participate in moderate-vigorous intensity exercise * able to read, write, and understand english * ability to understand and the willingness to sign an informed consent document * willing to undergo two venous blood draws for the study exclusion criteria: * pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist * participants with uncontrolled intercurrent illness, as determined by the treating oncologist * participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist * participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)

Keywords: ovarian cancer ovarian carcinoma ovarian cancer stage iv ovarian cancer stage iii ovarian cancer stage 3 endometrial cancer aerobic exercise strength training cardiovascular training
service development of pocus in the ibd clinic

Conditions: Inflammatory Bowel Diseases

Summary: study to determine whether the use of an ultrasound completed during an inflammatory bowel disease (ibd) clinic will speed up diagnosis, treatment initiation, reduce complications, save money and reduce investigations compared with our current standard of care.

after being provided with study information and providing written informed consent, participants attending the inflammatory bowel disease clinic will be randomised to standard of care or to receiving an ultrasound during the clinic appointment. this ultrasound result will be used to determine treatment decisions. participants will have a 6 month follow-up to capture outcome data and further medical record review will be conducted at one year.

Eligibility criteria:
inclusion criteria: * age 16 years or above * attending ibd clinic face-to-face * able to give informed consent. * belonging to one of the following groups: 1. new patients with high clinical suspicion of ibd 2. known uc/ibd-u and possible flare 3. known crohn's and possible flare 4. known ibd and assessing response to a new medication or following surgery 5. known ibd and clinician planning endoscopic or radiological investigations exclusion criteria: * inflammatory bowel disease limited to proctitis with no clinical suspicion of extension

Keywords: intestinal ultrasound
a multiple ascending dose study of pul-042 in stem cell transplant recipients

Conditions: Hematologic Diseases; Stem Cell Transplants

Summary: subjects with hematologic malignancies or recipients of a first allogenic or autologus hematopoietic stem cell transplant, without any evidence or respiratory infection, will receive 4 doses of pul-042 inhalation solution over a 2 week period. subjects will be evaluated for tolerability of the drug. if tolerated, dose escalation may occur with up to 4 dose levels tested

this is an open-label multiple ascending dose study with a 3+3 study design to examine the safety and tolerability of pul-042 inhalation solution in subjects with hematologic malignancies or recipients of a first allogenic or autologus hematopoietic stem cell transplant. subjects will receive 4 doses over 2 weeks. cohort size will be 3 subjects, once 3 subjects have completed treatment and follow-up at a dose level, subject data will be evaluated by an independent data safety monitoring committee prior to dosing additional subjects. the committee may recommend increasing the dose, maintaining the same dose, or decreasing the dose. once the maximum dose is determined, there may be up to 6 additional subjects dosed at that level.

Eligibility criteria:
inclusion criteria: 1. subjects with hematologic malignancies or recipients of a first allogeneic or autologous hematopoietic stem cell transplantation and presently clinically stable 2. pulse oximetry of hemoglobin saturation ≥92% on room air 3. adult (≥18 years) 4. spirometry (fev1 and forced vital capacity \[fvc\]) ≥80% of predicted value 5. if female, must be either post-menopausal (one year or greater without menses), surgically sterile, or, for female subjects of child-bearing potential who are capable of conception must be: practicing two effective methods of birth control 6. if female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study 7. if male, must be surgically sterile or willing to practice two effective methods of birth control 8. ability to understand and give informed consent exclusion criteria: 1. subjects with any evidence of respiratory infection including any signs or symptoms of either a lower respiratory infection (lri) or upper respiratory infection (uri) 2. known history of chronic pulmonary disease 3. subjects who are being treated for fungal, viral, or bacterial pneumonia 4. exposure to any investigational agent (defined as any agent not approved by the food and drug administration \[fda\]) within 30 days prior to the screening visit 5. patients with a relapsed and/or refractory underlying hematologic malignancy 6. hsct recipients who underwent ex vivo t-cell depletion of the graft, or a mismatched, or cord or haplo identical blood transplantation 7. hsct recipients with active and/or chronic graft versus host disease 8. patients on systemic corticosteroids (oral or intravenous) 9. absolute neutrophil count (anc) \< 1,000 cells/ml 10. clinically significant bacteremia or fungemia 11. current smokers or subjects with any history of smoking
a research study to see how well cagrisema helps people with excess body weight lose weight

Conditions: Obesity

Summary: this study has 2 parts: first part is the main study and second part is the extension study. during the main study participants will receive 1 of 4 study medicines. if participants continue in the extension study, they will not receive any study medicine during the extension. the main study will look at how well cagrisema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. participants will either get cagrisema, cagrilintide,semaglutide or "dummy" medicine. which treatment participants get is decided by chance. they will take one injection once a week. the study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms. extension study: after the main study, not all participants will continue in the extension study. the study staff will tell the participant if they will continue or not into the extension study. in the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. the main study will last for about 1½ years and the extension study will last for another 2 years.


Eligibility criteria:
inclusion criteria: * male or female * age above or equal to 18 years at the time of signing informed consent * body mass index (bmi) greater than or equal to 30.0 kilograms per square meter (kg/m\^2) or b) bmi greater than or equal to 27.0 kg/m\^2 with the presence of at least one weight-related comorbidity including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease exclusion criteria: - glycaemia related: a) glycated haemoglobin (hba1c) greater than or equal to 6.5 percent (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening b) history of type 1 or type 2 diabetes mellitus
phase 3 study of ym060 in patients with diarrhea-predominant irritable bowel syndrome (d-ibs)

Conditions: Irritable Bowel Syndrome

Summary: this study will examine the efficacy, safety and tolerability of oral dose of ym060, 5-ht3 receptor antagonist, in patients with d-ibs.


Eligibility criteria:
inclusion criteria: * patients satisfying the rome ii diagnostic criteria. * patients in whom no organic changes were observed in large intestine. exclusion criteria: * patients have diseases which interfere with evaluation of the efficacy and safety in this study. * patients are receiving and/or have received prior to the enrollment the treatment which interfere with evaluation of the efficacy and safety in this study.

Keywords: irritable bowel syndrome, diarrhea
home-based exercise intervention for patients with metastatic prostate cancer

Conditions: Castration-resistant Prostate Cancer; Androgen Deprivation Therapy

Summary: this single arm, multi-site pilot study aims to evaluate the feasibility of recruiting and adherence to a 12 week home-based exercise intervention to be conducted in men with metastatic castration resistant prostate cancer (mcrpc) receiving androgen deprivation therapy (adt). thirty patients will be enrolled, with the expectation that 20-25 will complete all follow-up measures.

the purpose of this trial is to evaluate the feasibility and adherence to a home-based 12 week exercise intervention in mcrpc patients receiving adt. it will also examine if a home-based exercise intervention can improve muscle strength, body composition, physical function, cardiopulmonary function fatigue, and patient reported outcomes (fatigue, depression, quality of life (qol)).

Eligibility criteria:
inclusion criteria: * metastatic disease that has progressed despite castrate levels of testosterone (surgically or medically castrated, with testosterone levels of \< 50 ng/dl) receiving adt. this will be verified by assessing total testosterone levels within 4 weeks prior to enrollment. * no current chemotherapy. * patients may be receiving additional hormonal therapy agents including but not limited to antiandrogens (e.g. bicalutamide, enzalutamide) and cyp17 inhibitors (e.g. abiraterone). * ability to engage safely in moderate exercise as determined by their treating physician. * not previously engaged in regular exercise training (\ 30 min/d or \<90 mins per week total including strength training, aerobic training, or walking) in the past 6 months. * access to a computer or a smart phone for syncing and uploading wearable activity data. * be able to speak and read english. exclusion criteria: * any condition that causes severe pain with exertion. * history of bone fractures. * active cardiovascular disease including any of the following: * new york heart association (nyha) grade ii or greater congestive heart failure . * history of myocardial infarction or unstable angina within 6 months prior to day 1. * history of stroke or transient ischemic attack within 6 months prior to day 1. * acute or chronic respiratory disease that is severe enough to compromise the ability of the participant to safely engage in exercise training protocol. * acute or chronic bone/joint/muscular abnormalities compromising their ability to exercise. * neurological conditions that affect balance and, or muscle strength. * dementia, altered mental status or any psychiatric condition prohibiting the understanding or rendering of informed consent.

Keywords: exercise hormone therapy
effects of trans-obturator tape outside-in versus inside-out procedure for stres urinary incontinence

Conditions: Quality of Life; Sexual Dysfunction

Summary: the investigators think that the two techniques of tot (inside-out and outside-in) procedures both statistically improve the sexual functions, psychosocial state and quality of life after the surgery. additionally postoperative physical and behavioral-emotional scores in pisq-12 were statistically more increase in inside-out group than the outside-in group.


Eligibility criteria:
inclusion criteria: * pure urodynamic sui * sexual active before and 2 months after the surgery * married or single * aged over 20 * have cured after tot operation exclusion criteria: * preoperative or postoperative detrusor disfunction * previous history of malignancy * prior vaginal surgery * a partner with sexual incapabilities * a concomitant gynecologic disorder * patients with pelvic organ prolapse over stage ii * pelvic radiotherapy and a history of psychological diseases * participants who had no sexual activity with in the past two months
comparison of environmental factors between the areas of over- and under-incidence of crohn's disease in the haut de france region, by the study of dental exposomes

Conditions: Environmental Exposure

Summary: the aim of this preliminary observational study is to compare external exposomes from 10 teeth issued through 10 subjects living in high incidence of crohn's disease area and 10 teeth issued through 10 subjects living in low incidence of crohn's disease area.


Eligibility criteria:
inclusion criteria: * adults subjects living in high and low incidence of crohn's disease areas and needing a dental extraction for medical indication exclusion criteria: * smokers during 10 last years

Keywords: dental exposome
medium chain fatty acids and ketones

Conditions: Diet, Healthy; Health

Summary: 16 participants were randomized to complete two seven-day intervention periods with twice-daily consumption of medium-chain fatty acids (mct) or long-chain fatty acids (lct) oil. before and after each intervention, participants completed a five-hour experimental day evaluating the response to a first intake of the mct or lct oils (pre mct or lct), which was repeated after the intervention period of daily intake (post mct or lct) (fig. the intervention periods were separated by a 2-4-week washout period.

prior to the experimental days, the participants abstained from alcohol and vigorous physical activity and consumed a controlled, eucaloric diet comprising 30 energy % (e%) fat, 52 e% carbohydrate, and 18e% protein to ensure similar conditions before each experimental day. on the experimental days, participants arrived by passive transport in the overnight fasted state (12 h) at 8 a.m at the institute. at arrival, participants were weighed, and body composition was determined using dual-energy x-ray absorptiometry (dxa). then a catheter was inserted into an antecubital vein. following 30 min of supine rest, whole-body oxygen uptake and substrate oxidation were determined, whereafter a basal venous blood sample was obtained. subsequently, participants ingested a test drink containing 35g of mct or lct oil diluted in 100g of a low-fat, low-carbohydrate cocoa milk within five min. 100 ml water was provided together with the test drink. participants were blinded to the type of oil intake on the experimental days. the participants were then followed for five hours. venous blood samples and indirect calorimetry measurements were performed frequently during the five hours. participants rested in a bed throughout the test day. following the first test day, a seven-day intervention period (chronic intake) with twice-daily consumption of mct or lct oil was conducted. during the seven days of daily oil intake, the participants ingested 2x10g oil in 15g cocoa milk on day 1-2, 2x20g oil in 30g cocoa milk on day 3-5, and 2x30g oil in 40g cocoa milk on day 6-7. this corresponded to 812kj on day 1-2, 1625kj on day 3-5, and 2413kj on day 6-7. the participants were instructed to maintain their habitual dietary patterns and physical activity level during the intervention. the participants were instructed to consume the oil together with breakfast and dinner and were supervised to ensure compliance. after the chronic intake period, a second experimental day (post), mirroring the one of the pre day, was conducted. after a wash-out period the intervention was repeated in a cross-over design.

Eligibility criteria:
inclusion criteria: * bmi between 20 and 35 * moderate physical activity level, defined as 1 to 3 weekly sessions of exercise. * non-smokers * no use of medicine * no known prediabetes or diabetes exclusion criteria: high habitual intake of mcfa (e.g., coconut milk, coconut oil, or dairy products), a ketogenic diet, known diabetes or pre-diabetes, use of medications, daily use of nicotine products

Keywords: medium-chain fatty acids ketones obesity
the embodied cognition: exploratory study of automatic and controlled processes in anorexia nervosa.

Conditions: Anorexia Nervosa

Summary: anorexia nervosa (an) is a common psychiatric illness, with severe prognosis (5% mortality) that has changed little over in half a century. one of the forms is the restrictive anorexia nervosa (anr). it consists of a phobia of weight gain and food with a massive food restriction. this pathology is studied in psychology but not using the theories of embodied cognition in which "perception and action" interact through sensorimotor processes. they are the source of attitudes (unconscious) towards certain stimuli and influence our interpretation (conscious).

the investigators hypothesis is that food restriction behavior is the result of two processes. one automatic and not conscious, which is an attraction toward food and manifests itself in the motivational attitudes of approach, and the other controlled and conscious, which prevents attraction to this type of stimuli and is manifested by motivational attitudes avoidance. these processes of attraction and avoidance are observed in embodied cognition paradigms because the answers induce movement of approach or avoidance of stimuli. the validation of these assumptions could lead to reconsideration of the respective roles of automatic and controlled processes in food behaviors of anorexics patients and to complete or refocus psychological techniques of care.

Eligibility criteria:
inclusion criteria for patients: * restrictive anorexia nervosa according to diagnostic and statistical manual of mental disorders text revision (dsm iv-tr) * bmi\> 16 to avoid the effects of undernutrition * start disorders \<10 years * right handed * having given free and informed consent prior to study participation * subject affiliated to the french national health insurance inclusion criteria for control group: * bmi between 18,5 and 25 * right handed * of school level paired in that of the patients (+/-1 the year) * having given free and informed consent prior to study participation * subject affiliated to the french national health insurance exclusion criteria for patients and control group: * patients with at the beginning or during the study form of purgative anorexia nervosa * control with disorders of current or past eating behavior. * control making a restrictive diet during the study period * participants with depressive table * participants with a somatic problem restricted movement or a problem of uncorrected visual acuity annoying reading of the screen.

Keywords: anorexia nervosa cognition conscious non-conscious